News! China Prostate Cancer Health Management and Testosterone Management Project launched

A domestic questionnaire survey conducted in October 2007 showed that 30%-54% of patients in China were terminal and metastasis diseases at first diagnosis, and the overall survival time and quality of life of patients were much lower than in Europe and the United States.
statistics, the five-year survival rate of prostate cancer patients in the United States can reach 97.4%, South Korea and Japan are also about 90%, while China is only 69.2%.
"China's prostate cancer health management project of excellence center of excellence" unveiling ceremony prostate cancer incidence and testosterone levels (i.e. male hormone) levels are closely related to reducing testosterone levels can inhibit the development of prostate cancer, so androgen removal therapy (ADT treatment, also known as endocrine therapy) is the standard treatment for local progression period and metastatic prostate cancer.
, however, the survival rate of prostate cancer patients in China is low, further highlighting the importance of "standard treatment and long-term follow-up", testosterone management standardization is one of the important work.
on December 12, 2020, the 10th International Forum on Urological Oncology and the Chinese Anti-Cancer Association's Special Committee on Urological Male Oncology, 2020, and the Prostate Cancer Task Force of the Chinese Society of Clinical Oncology, held in Hangzhou, Zhejiang Province, during the 2020 Session. The Chinese Anti-Cancer Association's Professional Committee on Oncology (CACA-GU), the Chinese Physicians Association's Urologist Branch (CUDA) and the China Primary Health Care Foundation (CPHCF) jointly sponsored the Testosterone Management Project for Prostate Cancer Health Management in China (IPCTM Project).
the project set up a special China prostate cancer testosterone management project expert committee and the first batch of project collaboration groups.
Under the leadership of the Project Expert Committee, the first batch of collaboration groups will be composed of 30 core units nationwide, through the construction of offline and offline combination of professional education platform to enhance China's prostate cancer DTR (Deep Testosterone Reduction) testosterone management standardization, and thus improve the overall survival level of china's prostate cancer patients, to help achieve the goal of healthy China 2030.
It is understood that Fudan University Affiliated Oncology Hospital, Peking University First Hospital, Chinese People's Liberation Army General Hospital, Sichuan University Huaxi Hospital, Zhongshan University Affiliated Cancer Hospital and other 30 hospitals listed the establishment of "China's prostate cancer health management testosterone management project center of excellence", to promote the standardization of China's prostate cancer testosterone management core force.
The standardization of testosterone management in the diagnosis and treatment of prostate cancer, especially in endocrine therapy, is very important," said Professor Ye Dingwei, chairman of the expert committee of the China Prostate Cancer Testosterone Management Project, chairman of the Oncology Committee of the Department of Urology and Male Reproduction of the Chinese Anti-Cancer Association, and professor of urology at Fudan University-affiliated Oncology Hospital.
The concept of training clinicians in the diagnosis and treatment of prostate cancer testosterone standard management and DTR deep detocogenicity, improve the awareness of testosterone level norms monitoring, regulate testosterone follow-up behavior, but also enhance the patient's awareness of testosterone self-management, for the promotion of prostate cancer diagnosis and treatment in China is of great significance.
through the collaboration of many hospitals throughout the country, it can help to improve the standardization of DTR testosterone monitoring and management, and thus improve the overall survival level of prostate cancer patients in China.
" Professor Ye Dingwei at the unveiling ceremony to address the depth of ketone testosterone management needs to be standardized according to Zhongshan University Cancer Prevention center urology director, the Chinese Anti-Cancer Association Of the Department of Urology, Professor Zhou Fangjian, deputy chairman of the Oncology Committee, the current medical institutions in the treatment, the beginning is only testosterone, descending treatment, doctors rarely pay attention to the patient's testosterone level.
, in fact, testosterone levels fluctuate after treatment, with a significant proportion of patients having testosterone levels between 50 and 20 ng/dl.
now we recommend paying close attention to testosterone levels after surgery to further enhance our understanding of ketones.
professor Zhou Fangjian, director of urology at Sun Yat-sen University's Cancer Prevention and Control Center and vice chairman of the Oncology Committee of the Department of Urology of the Chinese Anti-Cancer Association Chinese
Chinese Recent clinical studies by Professor Zhang Xu, Director of The Department of Urology and Chairman-in-Office of the Urology Branch of the Chinese Medical Association, show that reducing testosterone levels to 20 ng/dl or less after ADT treatment can significantly reduce the following benefits, including improved overall survival: 1) The rate of bio-relapse and metastasis of prostate cancer was higher, 2) the time between progression and de-effects against prostate cancer (CRPC) was significantly prolonged, and the longer the survival time after CRPC, and 3) the progression of disease in prostate cancer patients was significantly delayed to improve the overall survival of patients.
professor Zhou Liqun, president of the Urology Department (CUDA) of the Chinese Physicians Association and director of the Institute of Urology at Peking University's First Hospital, said that deep ketones had only recently been really proposed, and there is now a lot of literature confirming that the lower the level of testosterone in patients, the better the level, the lower the drop in testosterone, and then relatively good.
there are many guidelines that do not set the standard for the level of going from 50 ng/dl to 20 ng/dl.
, it is important to note that not all patients are treated with testosterone levels below 20 ng/dl.
Professor Zhou Liqun, President of the Urologist Branch (CUDA) of the Chinese Physicians Association and Director of the Institute of Urology at Peking University First Hospital, understands that under the guidance of the Expert Committee on The Management of Testosterone for Prostate Cancer in China, well-known experts from all over the country will start writing a new edition of the China Consensus on the Management of DTR Testosterone for Prostate Cancer.
At the same time, the IPCTM project will establish 30 national DTR Testosterone Management Centers of Excellence to further enhance the concept of deep detox and testosterone management for clinicians through a series of activities such as the center of excellence's "band of help", multidisciplinary collaboration in DTR testosterone management, and clinical excellence case sharing discussions.
" testosterone management is generally relatively simple, in the past we did not pay attention to the changes in testosterone, now there is a consensus, patients every time they draw blood, testosterone can also be tested.
For doctors, need to understand that the patient's testosterone control is good, if not well controlled, need to intervene, especially early intervention, otherwise, the disease will develop, in this version of the Consensus will pay more attention to that part of the testosterone control patients to find out, improve his treatment effect.
, " said Professor Zhou Liqun.
Strengthen the management of the whole course of life of prostate cancer patients At present, prostate cancer ADT treatment includes surgical and drug removal, surgery to remove the potential can make testosterone rapidly and continuously drop to low levels, but the psychological impact on patients is greater, and drug removal can avoid the removal of testicles, only a certain amount of progesterone release hormone (GnRH) agonists or antagonists, can reduce testosterone concentration to the level.
For most prostate cancer patients, compared with surgery, drug dissocreation has the advantages of convenient administration, few adverse reactions, long-lasting efficacy, and is the main method of androgen deprivation treatment.
currently, china's listed GnRH astigid drugs are qurelin, gosherin and lignin three categories, all of which have long-acting dosage forms in January and March.
from the long-term treatment of prostate cancer, the March dosage form is convenient and economical, but also to improve patient compliance and optimize long-term patient management.
from the CDE official website information, the current GnRH agitant drug in June dosage form also entered the review center approval process, looking forward to June dosage form will bring more convenience to patients.
Ye Dingwei points out that more and more patients will choose long-acting preparations, and more and more patients will choose the March dosage form.
especially this year, during the outbreak, patients also tend to go to the hospital less, the outbreak makes queuing, appointments become inconvenient.
, both in terms of convenience and the quality of treatment, patients are willing to choose the March dosage form.
of prostate cancer throughout the diagnosis and treatment process, we can see that the concept has gradually become deeply rooted in the hearts of the people.
Professor Zhang Xu suggested that the younger generation of doctors, in the treatment of prostate cancer ADT, the core is the maximum depth of reduced testosterone levels, focusing on the observation of patients' testosterone levels and CRPC, especially after non-surgical treatment, we must pay attention to the patient's testosterone management, as far as possible to reach the depth of de-trending levels.
The ipCTM project was launched, and the team hopes to integrate the work of professional societies, domain experts, and public foundations to help clinicians regulate testosterone management and long-term follow-up in prostate cancer patients, achieve deep ketone reduction in treatment, improve patient survival benefits, and improve quality of life.
it is understood that, with the support of Ipsos China, the "Long-Term Management Public Welfare Project for Prostate Cancer Patients in China" was officially launched in October 2020 in a joint effort between the Urologist Branch of the Chinese Physicians Association (CUDA) and the China Primary Health Care Foundation (CPHCF).
believes that with the implementation of these two projects, they can better help clinicians optimize the management of prostate cancer patients, improve the awareness of patient disease self-management, so as to standardize the long-term treatment and compliance of patients, and ultimately benefit the vast number of prostate cancer patients.
。